Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
=== EC 1.3.3 With oxygen as acceptor === EC 1.3.3.1: dihydroorotate oxidase EC 1.3.3.2: Now EC 1.14.19.20 Δ7-sterol 5(6)-desaturase EC 1.3.3.3: coproporphyrinogen oxidase EC 1.3.3.4: protoporphyrinogen oxidase EC 1.3.3.5: bilirubin oxidase EC 1.3.3.6: acyl-CoA oxidase EC 1.3.3.7: dihydrouracil oxidase EC 1.3.3.8: tetrahydroberberine oxidase EC 1.3.3.9: Now EC 1.14.19.62 secologanin synthase EC 1.3.3.10: tryptophan a,b-oxidase EC 1.3.3.11: pyrroloquinoline-quinone synthase EC 1.3.3.12: l-galactonolactone oxidase
== Early life and career == Cantelmo was a high school valedictorian. He graduated from Yale University with a degree in molecular biophysics and biochemistry. He worked for about 35 years in the pharmaceutical industry, specializing in high-performance liquid chromatography (HPLC). According to his own accounts and those of family members, he ran three HPLC companies. The last of these was GL Sciences. He left that position prior to the events of 2019. GL Sciences has stated it has no association with Cantelmoism or the use of illegal drugs. Cantelmo had a history of mental health difficulties and prior suicide attempts. He had also used other substances, including mescaline, LSD, and methamphetamine, at earlier points in his life.
Number average molar mass (Mn), also loosely referred to as number average molecular weight (NAMW). Mass average molar mass (Mw), where w stands for weight; also commonly referred to as weight average or weight average molecular weight (WAMW). Z-average molar mass (Mz), where z stands for centrifugation (from German Zentrifuge). Viscosity average molar mass (Mv).
Dofetilide is a class III antiarrhythmic agent. It is marketed under the trade name Tikosyn by Pfizer, and is available in the United States in capsules containing 125, 250, and 500 μg of dofetilide. It is not available in Europe or Australia.
Sources: en.wikipedia.org
=== Neo === Counter-Strike Neo (stylized NEO) is a Japanese arcade adaptation of Counter-Strike published by Namco for Linux-based machines. The game is set in a futuristic version of Counter-Strike, with characters featuring anime-like designs. A selection of single-player missions, mini-games, and seasonal events were added to prolong the players' interest on the game.
Anode-free battery Blade battery Borate oxalate Comparison of commercial battery types European Battery Alliance Flow battery Nanowire battery Sodium-ion battery Thin-film lithium-ion battery VRLA battery Ultium
=== Staging === Sometimes backups are copied to a staging disk before being copied to tape. This process is sometimes referred to as D2D2T, an acronym for Disk-to-disk-to-tape. It can be useful if there is a problem matching the speed of the final destination device with the source device, as is frequently faced in network-based backup systems. It can also serve as a centralized location for applying other data manipulation techniques.
Surface charge practically always appears on the particle surface when it is placed into a fluid. Most fluids contain ions, positive (cations) and negative (anions). These ions interact with the object surface. This interaction might lead to the adsorption of some of them onto the surface. If the number of adsorbed cations exceeds the number of adsorbed anions, the surface would have a net positive electric charge. Dissociation of the surface chemical group is another possible mechanism leading to surface charge.
In addition to its role as a trypsin inhibitor, in rats it has also been found to stimulate the release of CCK from the enteroendocrine cells of the small intestine, and it has been called "monitor peptide" in this context. CCK then acts on the gallbladder to release bile and on the pancreas to release digestive enzymes, which help to further break down the food. This coordinated response helps to ensure efficient digestion and absorption of nutrients.
Sources: en.wikipedia.org
Pakatan Harapan defeated Barisan Nasional in the 2018 general election. Concerns for a smooth power transition emerged as Najib declared that no party had achieved a majority. The National Palace of Malaysia subsequently confirmed Mahathir would be sworn in as Malaysia's seventh prime minister, refuting any claims of delaying the appointment. Immediately after the declaration of the results, people in Kuala Lumpur expressed their joy in celebration of the historic victory. Mahathir announced a two-day public holiday, adding: 'But there will be no holidays for the winners.' He became the world's oldest serving state leader (aged 92 years, 304 days at the time), and the first Malaysian prime minister not to represent UMNO. Mahathir was also officially recognized by Guinness World Records as the world's oldest serving prime minister. His deputy, Wan Azizah Wan Ismail became the first female deputy prime minister of Malaysia. In April 2019, Mahathir was listed among Time magazine's 100 most influential people.
== History == The detection of nitrates and nitrites for GSR has been around since the early 1900s. The first recorded use of paraffin wax as a lifting medium was done by Dr. Iturrioz in 1914 and was popularized in 1933 by Teodoro Gonzalez of the Mexico City Police Laboratory. The aptly named paraffin test is also referred to as the diphenylamine test, dermal nitrate test and the Gonzalez test. This test consisted of coating a suspect's hands with paraffin wax, allowing it to solidify and peeling it away before adding a diphenylamine/sulfuric acid reagent. The presence of dark blue spots is said to indicate a positive result. This is no longer used in casework due to the high number of false positives caused by the commonality of nitrates and nitrites in a variety of mundane products such as fertilisers. In 1971 John Boehm presented some micrographs of gunshot residue particles found during the examination of bullet entrance holes using a scanning electron microscope. If the scanning electron microscope is equipped with an energy-dispersive X-ray spectroscopy detector, the chemical elements present in such particles, mainly lead, antimony and barium, can be identified. In 1979 Wolten et al. proposed a classification of gunshot residue based on composition, morphology, and size. Four compositions were considered characteristic:
=== Notable cases === As of April 2016, six hyperthymesia cases have been confirmed in peer-reviewed articles, the first being that of Jill Price (initially anonymised as "AJ") in 2006. More cases had been identified by 2012, but are yet to be published. Price's case was originally reported by researchers from the University of California, Irvine, Elizabeth Parker, Larry Cahill and James McGaugh, and is credited as being the first documented case of hyperthymesia. Price can apparently recall every day of her life from when she was 14 years old: "Starting on February 5, 1980, I remember everything. That was a Tuesday." In March 2009, Price was interviewed for an article in Wired magazine by Gary Marcus, a cognitive psychologist at New York University. Price's brain had been subject to a brain scan and the hippocampus and prefrontal cortex had been reportedly normal. Marcus claimed, however, that her brain resembled "those of people with obsessive-compulsive disorder" and suggested that her remarkable memory might be "the byproduct of obsession", claiming also that "the memory woman clings tightly to her past". Price strongly disputed this and McGaugh has also challenged the explanation. Price gave her first interview in over a year for the UK's Channel 4 documentary The Boy Who Can't Forget, and spoke of the challenges of living with the condition. K.
1993/2629) Shropshire's Community Health Service National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2630) Hill Livestock (Compensatory Allowances) Regulations 1993 (S.I. 1993/2631) National Lottery etc. Act 1993 (Commencement No. 1 and Transitional Provisions) Order 1993 (S.I. 1993/2632) South East London Mental Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2633) Haringey Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2634) North Staffordshire Combined Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2635) Lincoln District Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2636) Swindon and Marlborough National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2637) Louth and District Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2638) North Kent Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2639) Medway National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2640) Queen Victoria Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2641) Dartford and Gravesham National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2642) Worthing and Southlands Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2643) Gipsy Encampments (Borough of Holderness) Order 1993 (S.I. 1993/2644) Norfolk Mental Health Care National Health Service Trust (Establishment) Order 1993 (S.I.
=== Therapeutic === Activation of the NRF2 (nuclear factor erythroid 2–related factor 2) pathway has been explored as a therapeutic strategy due to its role in regulating antioxidant and cytoprotective responses. One of the most clinically advanced NRF2 activators is dimethyl fumarate, marketed as Tecfidera by Biogen Idec. It was approved by the Food and Drug Administration in March 2013 following a successful Phase III clinical trial that demonstrated reduced relapse rates and delayed progression of disability in individuals with multiple sclerosis. Although the precise mechanism of action of dimethyl fumarate is not fully understood, it is known to activate the NRF2 signaling pathway. Both dimethyl fumarate and its active metabolite, monomethyl fumarate, promote NRF2 nuclear translocation and the subsequent transcription of antioxidant response element (ARE)-driven genes. In addition, they have been shown to act as nicotinic acid receptor agonists in vitro. Despite its clinical efficacy, dimethyl fumarate is associated with several adverse effects, including anaphylaxis, angioedema, progressive multifocal leukoencephalopathy (PML), lymphopenia, and liver damage. Common side effects include flushing and gastrointestinal symptoms such as diarrhea, nausea, and upper abdominal pain. Other NRF2 activators have also been investigated. The dithiolethiones are a class of organosulfur compounds known to induce NRF2 activity. Among them, oltipraz is the most extensively studied.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.